Publications by authors named "K Frank-Raue"
Article Synopsis
- Early screening for elevated calcitonin levels and RET gene mutations in families with MEN2 significantly improves cure rates for hereditary medullary thyroid carcinoma (MTC) through prophylactic thyroidectomy.
- A long-term study tracked 277 MEN2 patients post-thyroidectomy for an average of 14.4 years, revealing that 55.6% achieved long-term cures.
- Factors influencing long-term success included younger age at surgery and lower tumor stage, indicating that timely intervention based on mutation risk is crucial for maintaining low calcitonin levels.
Background: Menopausal estrogen depletion increases the risk of cardiovascular disease and of osteoporosis. Both of these risks can be increased by thyroid dysfunction as well. This cumulation of risks will be presented.
View Article and Find Full Text PDFBackground: (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of status. The actual outcome of patients with -positive MTC treated with MKIs is ill described.
View Article and Find Full Text PDFObjective: Ectopic Cushing's syndrome (ECS) induced by medullary thyroid cancer (MTC) is rare, and data on clinical characteristics, treatment and outcome are limited.
Design: Retrospective cohort study in three German and one Swiss referral centres.
Patients: Eleven patients with MTC and occurrence of ECS and 22 matched MTC patients without ECS were included.
Objectives: Procalcitonin (PCT) has been suggested as a tumor marker in patients with medullary thyroid carcinoma (MTC). Clinical application data in long term follow-up are missing.
Methods: 210 serum samples of 169 consecutive patients with MTC (92 sporadic, 77 hereditary, 158 postoperative follow-up, 11 preoperative) were collected between 2018 and 2020.